Fluidigm Joins AMDeC Vendor Partnership Program, Gaining Access to World-Class New York-Area Academic Research Institutions Through AMDeC F.I.R.S.T.™

A Web-Based Catalogue of 1000+ Instruments and Services, AMDeC F.I.R.S.T. is Accessed by Researchers from Almost 20 Institutions

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today announced it has joined AMDeC (Academy for Medical Development and Collaboration) as a Vendor Partner. This will provide Fluidigm with easy access to almost 20 of the pre-eminent medical research institutions in the New York region through AMDeC’s unique online resource - AMDeC F.I.R.S.T. - while also providing preferred pricing on select Fluidigm products to all AMDeC Member institutions.

“Fluidigm is delighted to become a partner with the prestigious membership of AMDeC. Being a leader in single-cell analysis, we know that our technologies will enable AMDeC researchers to see cellular behaviors and processes that were previously hidden by using pooled samples”

AMDeC F.I.R.S.T. (Facilities Instrumentation Resources Services & Technologies) is a powerful web-based platform and real-time registry that catalogs more than 1,000 services and instruments from across the AMDeC Member consortium. It serves as the portal to several AMDeC services, including the Vendor Partnership Program joined by Fluidigm. This program secures preferred vendor pricing agreements for all AMDeC Members. Benefits for Vendor Partners include facilitated access to researcher end users, research directors and other institutional decision makers, as well as closer working relationships with the academic research community.

AMDeC F.I.R.S.T. creates a virtual “laboratory” that can be leveraged by researchers for collaboration and shared use. It expands and extends the research resources of every Member institution, facilitating the sharing of resources, and delivering the potential to reduce or recover costs, achieve resource efficiencies, foster new collaborations and expedite discovery.

“Fluidigm is delighted to become a partner with the prestigious membership of AMDeC. Being a leader in single-cell analysis, we know that our technologies will enable AMDeC researchers to see cellular behaviors and processes that were previously hidden by using pooled samples,” said Dan Clutter, Ph.D., Sales Director, Eastern U.S. for Fluidigm.

Fluidigm Products Simplify Experimental Workflow

As a Vendor Partner, Fluidigm will offer preferred pricing on a broad range of instruments, reagents, and assay design services. Fluidigm is the world’s creator of integrated fluidic circuits, a unique microfluidic technology that provides the equivalent of an “integrated circuit for biology.” Fluidigm’s technology enables rapid, efficient and reproducible analysis of hundreds of genetic markers, across thousands of DNA samples – in just hours instead of days or weeks.

The company’s cutting edge microfluidic systems consist of instruments and consumables, including chips, assays and other reagents designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing excellent data quality. Fluidigm’s technology enables genetic analysis that in many instances was previously impractical.

Fluidigm’s product lines serve researchers conducting high-throughput gene expression analysis, production genotyping and digital PCR, target enrichment for next-generation sequencers, and single-cell analysis. In June, Fluidigm introduced its new C₁™ Single-Cell AutoPrep System to enable researchers to isolate and process individual cells rapidly and reliably for genomic analysis.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements relating to the partnership program and Fluidigm products and services. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including the risk factors contained in Fluidigm’s filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.

About AMDeC

Since its founding in 1997, AMDeC has led the way in team science, resource-sharing efforts, member services focused on cost savings and technology access, and private sector participation with academia. AMDeC creates programs and services, such as AMDeC F.I.R.S.T., and the Vendor Partnership Program to facilitate collaboration and efficient use of resources, with the goal of expediting discovery by its Members, which include many of the world’s most prestigious medical research institutions. In addition to Fluidigm, AMDeC Vendor Partners also include: Access Scientific, AchievIt, Acumenta Corporation, iLab Solutions, NuGEN Technologies, QIAGEN, Inc, Sigma Life Science, and Xiacon.

For more information please visit www.amdecllc.com or contact [e-mail].

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including nine different commercial chips, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use).

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo and C₁ are trademarks or registered trademarks of Fluidigm Corporation.